rosiglitazone has been researched along with Albuminuria in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.33) | 18.2507 |
| 2000's | 20 (66.67) | 29.6817 |
| 2010's | 9 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, J; Li, H; Wang, Q; Xu, J; Zhang, Y; Zhao, S | 1 |
| Chodavarapu, H; Elased, KM; Grobe, N; Madhu, M; Salem, ES; Somineni, HK | 1 |
| Channer, KS; Jones, TH; Kapoor, D | 1 |
| Brosius, FC; Byun, J; Feldman, EL; Kennedy, RT; Kretzler, M; Lorenz, M; Pennathur, S; Saha, J; Schin, M; Zhang, H | 1 |
| Glover, PH; Jones, AV; Maric, C; McLemore, GR; Racusen, LC; Reckelhoff, JF; Ryan, MJ; Sartori-Valinotti, JC; Venegas-Pont, M | 1 |
| Chen, K; Chen, Y; Li, XC; Wang, YX; Yao, XM; Ye, SD; Zai, ZM | 1 |
| Jones, AV; Lamarca, BB; Racusen, LC; Reckelhoff, JF; Romero, DG; Ryan, MJ; Sartori-Valinotti, JC; Venegas-Pont, MR; Yanes, LL | 1 |
| Bob, F; Bozdog, G; Dragos Jianu, C; Dumitrascu, V; Gadalean, F; Giju, S; Gluhovschi, C; Gluhovschi, G; Ianculescu, C; Marian, R; Petrica, L; Petrica, M; Ursoniu, S; Velciov, S; Vlad, A | 1 |
| Chu, SH; Chun, SH; Li, AH | 1 |
| Georgianos, PI; Lasaridis, AN; Sarafidis, PA; Saratzis, AN; Stafylas, PC | 1 |
| Cruzado, JM; Flaquer, M; Franquesa, M; Grinyó, JM; Herrero-Fresneda, I; Lloberas, N; Rosa, JL; Torras, J; Vidal, A | 1 |
| Barone, F; Bilous, R; Buckingham, R; Dessapt, C; Gnudi, L; Gruden, G; Hayward, A; Hiroshi, K; Setti, G; Viberti, G; White, K | 1 |
| Aftring, RP; Haffner, SM; Herman, WH; Holman, RR; Kahn, SE; Kravitz, BG; Lachin, JM; Paul, G; Viberti, G; Zinman, B | 1 |
| Cherian-Shaw, M; Hammock, BD; Hye Khan, MA; Imig, JD; Nagasawa, T; Shaw, SM; Walsh, KA | 1 |
| Berry, RA; Freed, MI; Greene, DA; Haffner, SM; Heise, MA; Herman, WH; Holman, RR; Jones, NP; Kahn, SE; Lachin, JM; Levy, D; Viberti, G; Zinman, B | 1 |
| Bakris, G; Freed, MI; Heise, M; Porter, LE; Viberti, G; Weston, WM | 1 |
| Grossman, E | 1 |
| Viberti, GC | 1 |
| Evans, M; Rees, A; Roberts, AW; Thomas, A | 1 |
| Kiselevich, A; London, D; Magen, E; Priluk, R; Viskoper, RJ; Volchek, L; Yosefy, C | 1 |
| Hitoglou-Makedou, AD; Lasaridis, AN; Nilsson, PM; Pagkalos, EM; Pliakos, CI; Sarafidis, PA; Tourkantonis, AA; Yovos, JG | 1 |
| Fischer, S; Gross, P; Herbrig, K; Kindel, B; Passauer, J; Pistrosch, F | 1 |
| Os, I | 1 |
| Bakris, GL; Sarafidis, PA | 1 |
| Bakris, GL; Freed, MI; Heise, MA; McMorn, SO; Porter, LE; Ruilope, LM; Weston, WM | 1 |
| Cersosimo, E; DeFronzo, RA; Miyazaki, Y; Triplitt, C | 1 |
| Guan, Y; Zheng, F | 1 |
| Al-Barazanji, KA; Bond, B; Buckingham, RE; Clapham, JC; Connor, SC; Slaughter, M; Toseland, CD; Turner, NC; West, A | 1 |
| Janka, HU | 1 |
| Valensi, P | 1 |
7 review(s) available for rosiglitazone and Albuminuria
| Article | Year |
|---|---|
Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis.
Topics: Albuminuria; Diabetic Nephropathies; Disease Progression; Humans; Hypoglycemic Agents; Pioglitazone; PPAR gamma; Proteinuria; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al.
Topics: Albuminuria; Blood Pressure Determination; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Prognosis; Risk Assessment; Risk Factors; Rosiglitazone; Sensitivity and Specificity; Thiazoles; Thiazolidinediones | 2003 |
Rosiglitazone: potential beneficial impact on cardiovascular disease.
Topics: Albuminuria; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Obesity; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Topics: Albuminuria; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Carotid Arteries; Coronary Restenosis; Diabetes Mellitus, Type 2; Endothelin-1; Endothelium, Vascular; Humans; Hyperglycemia; Insulin Resistance; Lipoproteins; Matrix Metalloproteinases; Metformin; Muscle, Smooth, Vascular; Pioglitazone; Plasminogen Activator Inhibitor 1; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2003 |
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.
Topics: Albuminuria; Animals; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin-1; Humans; Hypoglycemic Agents; Kidney; Kidney Failure, Chronic; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors; Troglitazone | 2006 |
[Glitazones. Profile of a new class of substances].
Topics: Albuminuria; Animals; Anticholesteremic Agents; Chromans; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Germany; Humans; Hypoglycemic Agents; Isoenzymes; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2001 |
[Rosiglitazone: a clinical development focused on cardio-vascular prevention].
Topics: Albuminuria; Animals; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans; Hypoglycemic Agents; Plasminogen Activator Inhibitor 1; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
10 trial(s) available for rosiglitazone and Albuminuria
| Article | Year |
|---|---|
Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes.
Topics: Adiposity; Adult; Aged; Albuminuria; Blood Pressure; Body Size; C-Reactive Protein; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Hypogonadism; Intra-Abdominal Fat; Lipids; Longitudinal Studies; Male; Middle Aged; Pilot Projects; Rosiglitazone; Sex Hormone-Binding Globulin; Testosterone; Thiazolidinediones; Treatment Outcome; Up-Regulation | 2008 |
Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial.
Topics: Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Neuroprotective Agents; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2009 |
Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.
Topics: Adult; Aged; Albuminuria; Blood Glucose; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Follow-Up Studies; Glomerular Filtration Rate; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2011 |
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
Topics: Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Glyburide; Humans; Hypoglycemic Agents; Metformin; Research Design; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Time Factors; Treatment Failure; Treatment Outcome | 2002 |
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
Topics: Administration, Oral; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Kidney Function Tests; Male; Middle Aged; Reference Values; Rosiglitazone; Sensitivity and Specificity; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity.
Topics: Administration, Oral; Albuminuria; Blood Glucose; Blood Pressure; Body Mass Index; Brachial Artery; Cholesterol, LDL; Cilazapril; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Endothelial Cells; Endothelium, Vascular; Evoked Potentials; Female; Glyburide; Glycated Hemoglobin; Heart Rate; Humans; Hyperlipidemias; Hypertension; Insulin; Insulin Resistance; Kidney; Male; Rosiglitazone; Simvastatin; Skin Physiological Phenomena; Sympathetic Nervous System; Thiazolidinediones; Time Factors; Ultrasonography; Vasodilation | 2004 |
The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension.
Topics: Aged; Albuminuria; Blood Pressure; Diabetes Mellitus, Type 2; Electrolytes; Female; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Kidney; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Vasodilator Agents | 2005 |
Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients.
Topics: Aged; Albuminuria; Cross-Over Studies; Diabetic Nephropathies; Double-Blind Method; Endothelium, Vascular; Female; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Kidney; Kidney Glomerulus; Male; Middle Aged; Placebos; Rosiglitazone; Thiazolidinediones | 2005 |
Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Blood Pressure; Cohort Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones | 2006 |
Rosiglitazone decreases albuminuria in type 2 diabetic patients.
Topics: Adiponectin; Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Fatty Acids, Nonesterified; Glucose; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Linear Models; Middle Aged; Multivariate Analysis; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2007 |
13 other study(ies) available for rosiglitazone and Albuminuria
| Article | Year |
|---|---|
PPAR-γ agonist rosiglitazone ameliorates peritoneal deterioration in peritoneal dialysis rats with LPS-induced peritonitis through up-regulation of AQP-1 and ZO-1.
Topics: Albuminuria; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aquaporin 1; Gene Expression Regulation; Hemodialysis Solutions; Lipopolysaccharides; Male; Peritoneal Dialysis; Peritoneum; Peritonitis; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Urea; Zonula Occludens-1 Protein | 2018 |
Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion.
Topics: ADAM Proteins; ADAM17 Protein; Albuminuria; Angiotensin-Converting Enzyme 2; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucose Tolerance Test; Glycosuria; Hyperglycemia; Hypoglycemic Agents; Kidney Diseases; Male; Membrane Proteins; Mice; Peptidyl-Dipeptidase A; Rosiglitazone; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-3; Triglycerides | 2013 |
Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy.
Topics: Albuminuria; Animals; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Hypoglycemic Agents; Male; Mice; Mice, Inbred DBA; Oxidative Stress; Podocytes; Rosiglitazone; Spectrometry, Mass, Electrospray Ionization; Thiazolidinediones; Urine | 2008 |
Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus.
Topics: Albuminuria; Animals; Antihypertensive Agents; Blood Pressure; Chemokine CCL2; Disease Models, Animal; Endothelin-1; Female; Hypertension; Kidney; Kidney Diseases; Lupus Erythematosus, Systemic; Macrophages; Mice; Monocytes; Osteopontin; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2009 |
Rosiglitazone protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase-9 expression.
Topics: Albuminuria; Animals; Case-Control Studies; Diabetes Mellitus, Experimental; Disease Models, Animal; Hypoglycemic Agents; Kidney; Male; Matrix Metalloproteinase 9; Rats; Rats, Wistar; Retinol-Binding Proteins; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2009 |
Rosiglitazone reduces blood pressure in female Dahl salt-sensitive rats.
Topics: Albuminuria; Animals; Biomarkers; Blood Glucose; Blood Pressure; Body Weight; Chemokine CCL2; Cholesterol; Estradiol; Feeding Behavior; Female; Gene Expression Regulation; Immunohistochemistry; Inflammation; Insulin; Kidney; Leptin; Nitrates; Nitrites; Osteopontin; Ovariectomy; Rats; Rats, Inbred Dahl; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2010 |
Association of proliferative diabetic retinopathy with insulin use and microalbuminuria.
Topics: Albuminuria; Angiogenesis Inhibitors; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Humans; Hypoglycemic Agents; Insulin; Macular Edema; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2010 |
The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats.
Topics: Albuminuria; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Hypoglycemic Agents; Immunosuppressive Agents; Male; Protein Phosphatase 2; Rats; Rats, Sprague-Dawley; Rosiglitazone; Sirolimus; Thiazolidinediones; Transcription Factors; Transforming Growth Factor beta1 | 2010 |
Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes.
Topics: Albuminuria; Animals; Cells, Cultured; Chemokine CCL2; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoglycemic Agents; Kidney; Macrophages; Male; Membrane Proteins; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2010 |
Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats.
Topics: Albuminuria; Animals; Blood Pressure; Cardiomegaly; Epoxide Hydrolases; Hypertension; Hypoglycemic Agents; Kidney Glomerulus; Macrophages; Male; Obesity; PPAR gamma; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rosiglitazone; Species Specificity; Syndrome; Thiazolidinediones | 2012 |
[PPARgamma agonists--antidiabetics with positive effects on cardiovascular risk?].
Topics: Albuminuria; Atherosclerosis; Blood Pressure; Cardiovascular Diseases; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipoproteins; Pioglitazone; PPAR gamma; Risk Factors; Rosiglitazone; Thiazolidinediones | 2005 |
Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy?
Topics: Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Humans; Hypoglycemic Agents; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2007 |
Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats.
Topics: Acetylglucosaminidase; Albuminuria; Animals; Blood Pressure; Body Weight; Histocytochemistry; Hypoglycemic Agents; Immunohistochemistry; Islets of Langerhans; Kidney; Kidney Diseases; Male; Obesity; Pancreas; Pancreatic Diseases; Proteinuria; Rats; Rats, Zucker; Rosiglitazone; Systole; Thiazoles; Thiazolidinediones | 1998 |